Research programme: IKACh modulators - Xention

Drug Profile

Research programme: IKACh modulators - Xention

Latest Information Update: 25 Mar 2016

Price : $50

At a glance

  • Originator Xention
  • Class Small molecules
  • Mechanism of Action Potassium channel modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Atrial fibrillation

Most Recent Events

  • 25 Mar 2016 Preclinical development of IKACh modulators for the treatment of Atrial fibrillation is ongoing in the United Kingdom
  • 12 Sep 2011 Preclinical trials in Atrial fibrillation in United Kingdom (PO)
  • 06 Jul 2009 Early research in Atrial fibrillation in United Kingdom (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top